Paper15728811
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
Kobayashi S and 9 others. N Engl J Med, 2005. Cited by 3,373 papers, by iCite.
Cite this record
ConductScience Library. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. Papers, record 15728811. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/15728811
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Case Reports, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| ErbB Receptors | Major topic |
| Lung Neoplasms | Major topic |
| Quinazolines | Major topic |
| Aged | |
| Biopsy | |
| DNA, Neoplasm | |
| Erlotinib Hydrochloride | |
| Gefitinib | |
| Humans | |
| Male | |
| Models, Structural | |
| Molecular Structure | |
| Neoplasm Recurrence, Local | |
| Point Mutation | |
| RNA, Neoplasm | |
| Sequence Analysis, DNA | |
| Sequence Analysis, RNA |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| 1K12CA87723-01 | NCI NIH HHS | United States | K12CA877230 | PubMed | NIH RePORTER |
| PA20-CA090578-01A1 | NCI NIH HHS | United States | PubMed | PubMed | |
| K12CA087723 | NIH | NIH RePORTER | |||
| P20CA090578 | NIH | NIH RePORTER | |||
| P50CA090578 | NIH | NIH RePORTER |
Trials5
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT01480141 | A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC) | Background | ClinicalTrials.gov | |
| NCT01542437 | Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer | Background | ClinicalTrials.gov | |
| NCT01562028 | BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC) | Background | ClinicalTrials.gov | |
| NCT01880515 | Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW2992 (Afatinib) | Background | ClinicalTrials.gov | |
| NCT05998993 | Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO) | Background | ClinicalTrials.gov |
Comments and corrections3
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 15728818 | Chasing mutations in the epidermal growth factor in lung cancer. | https://conductscience.org/library/papers/15728818 | PubMed |
| Comment in | 15901872 | EGFR mutation and response of lung cancer to gefitinib. | https://conductscience.org/library/papers/15901872 | PubMed |
| Comment in | 16264986 | EGFR point mutation confers resistance to gefitinib in a patient with non-small-cell lung cancer. | https://conductscience.org/library/papers/16264986 | PubMed |
Cited by1,832
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3,373 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42917883 | A Structural Perspective on Non-covalent Targeting of Conserved Polar Residues in Protein Kinases. | J Med Chem | 2026 | https://conductscience.org/library/papers/42917883 | PubMed |
| 42902326 | Cancer metastasis: biological mechanisms, therapeutic bottlenecks, and emerging interventions. | J Hematol Oncol | 2026 | https://conductscience.org/library/papers/42902326 | PubMed |
| 42845849 | Base gap switches as transcriptional regulators and their applications as biosensors. | Nat Sens | 2026 | https://conductscience.org/library/papers/42845849 | PubMed |
| 42774563 | Clinical and genomic determinants of early treatment discontinuation in non-small-cell lung cancer: an analysis of the AACR Project GENIE Biopharma Collaborative NSCLC dataset. | ESMO Real World Data Digit Oncol | 2026 | https://conductscience.org/library/papers/42774563 | PubMed |
| 42684344 | Epigenetic Profiling for Early Detection and Treatment Response Monitoring in Non-Small Cell Lung Cancer: Protocol for a Prospective Translational Biomarker Study. | JMIR Res Protoc | 2026 | https://conductscience.org/library/papers/42684344 | PubMed |
| 42656147 | Towards better outcomes for epidermal growth factor receptor L858R+ lung cancer patients: mutant-selective allosteric inhibitors and the potential for double-drugging. | Philos Trans R Soc Lond B Biol Sci | 2026 | https://conductscience.org/library/papers/42656147 | PubMed |
| 42589611 | Advances in Aptamer Diagnostics Targeting Non-Small-Cell Lung Cancer: A Systematic Review. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42589611 | PubMed |
| 42589609 | The Dual Role of Human UDP-Glucuronosyltransferase-Mediated Metabolism in Tumor Drug Resistance: Mechanisms and Prospects. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42589609 | PubMed |
| 42583967 | Epidermal growth factor receptor as a target enzyme in cancer therapy: Structural and functional insights from crystallography. | Indian J Pharmacol | 2026 | https://conductscience.org/library/papers/42583967 | PubMed |
| 42572587 | Mycoplasma infection drives EGFR-TKI resistance through convergent transcriptomic reprogramming in non-small cell lung cancer. | iScience | 2026 | https://conductscience.org/library/papers/42572587 | PubMed |
| 42514920 | Exploiting the T790M Gatekeeper: A Theoretical Blueprint for Non-Covalent Inhibition of in cis Triple-Mutant EGFR. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42514920 | PubMed |
| 42512348 | Risk Stratification and Strategies Towards Front-Line Therapy of EGFR-Mutant NSCLC: A Narrative Review. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42512348 | PubMed |
| 42463770 | Multiparatopic antibodies overcome tyrosine kinase inhibitor resistance by inducing lysosomal degradation of EGFR mutants. | Oncogene | 2026 | https://conductscience.org/library/papers/42463770 | PubMed |
| 42435178 | Targeting Lung Cancer Metabolism: Therapeutic Opportunities and Challenges. | Adv Exp Med Biol | 2026 | https://conductscience.org/library/papers/42435178 | PubMed |
| 42428346 | New and emerging strategies for targeting cancers: Challenges and opportunities (Review). | Oncol Lett | 2026 | https://conductscience.org/library/papers/42428346 | PubMed |
| 42420595 | Opportunities and challenges in the development of evolving EGFR inhibitors to overcome EGFR TKIs resistance. | Acta Pharmacol Sin | 2026 | https://conductscience.org/library/papers/42420595 | PubMed |
| 42384310 | Atomic degradation: chemical design strategies and immunotherapeutic mechanisms of radio-PROTACs. | Ann Nucl Med | 2026 | https://conductscience.org/library/papers/42384310 | PubMed |
| 42187561 | A Case of Primary EGFR T790M Mutation in Treatment-Naïve Advanced NSCLC: Clinical and Molecular Implications. | Curr Oncol | 2026 | https://conductscience.org/library/papers/42187561 | PubMed |
| 42176127 | Somatic mutation profiling by NGS-based liquid biopsy in advanced non-small cell lung cancer: frequency, clinical correlates, and prognostic significance. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42176127 | PubMed |
| 42174661 | Beyond Darwin: reactive heredity, burst-drift dynamics and eco‑evolutionary control of cancer. | Mol Cancer | 2026 | https://conductscience.org/library/papers/42174661 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/15728811
GET https://conductscience.org/api/papers/v1/15728811/cited_by?page=2